Since 1999, MedBridge has been a leading provider of development, turnaround, partnership advising and revenue cycle management services for ambulatory surgery centers and other healthcare facilities. The company's comprehensive end-to-end solutions enable steady growth while enhancing the bottom line. Led by a Santa Barbara-based team of more than thirty professionals, MedBridge is focused on freeing surgeons and specialists to spend their best energy healing patients. To learn more about MedBridge's expertise and solutions, visit http://www.medbridge.md/solutions
About VG Life Sciences, Inc.
San Marino, California-based VG Life Sciences, Inc., formerly known as Viral Genetics, discovers and develops drug therapies from two exclusively licensed platform technologies based on more than 60 patents: Metabolic Disruption (MDT) and Targeted Peptides (TPT). A physician-initiated Phase I clinical trial of an MDT compound in combination with Nexavar™ on Stage III and IV ovarian cancer patients is ongoing at the Cancer Therapy and Research Center of The University of Texas Health Science Center at San Antonio. A majority-owned subsidiary, VG Energy (www.vgenergy.net), is dedicated to exploring biofuel and agricultural applications for the MDT platform. Founded in 1994, the biotech company is researching treatments for drug-resistant cancer, Lyme disease, Strep, Staph and Sepsis, and HIV/AIDS.
|SOURCE VG Life Sciences, Inc.|
Copyright©2012 PR Newswire.
All rights reserved